The Conserved Molecular Determinants of Virulence in Dengue Virus

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2019 Mar 27

PMID 30911269

Citations 9

Authors

Zuleeza Ahmad

Chit Laa Poh

Affiliations

Soon will be listed here.

Abstract

Dengue virus belongs to the Flaviviridae family which also includes viruses such as the Zika, West Nile and yellow fever virus. Dengue virus generally causes mild disease, however, more severe forms of the dengue virus infection, dengue haemorrhagic fever (DHF) and dengue haemorrhagic fever with shock syndrome (DSS) can also occur, resulting in multiple organ failure and even death, especially in children. The only dengue vaccine available in the market, CYD-TDV offers limited coverage for vaccinees from 9-45 years of age and is only recommended for individuals with prior dengue exposure. A number of mutations that were shown to attenuate virulence of dengue virus and/or have been identified in the literature. The mutations which fall within the conserved regions of all four dengue serotypes are discussed. This review hopes to provide information leading to the construction of a live attenuated dengue vaccine that is suitable for all ages, irrespective of the infecting dengue serotype and prior dengue exposure.

Citing Articles

A Case of Dengue Fever With Multiserotype IgG Positivity.

Wheaton N, Lee D, Zinabu S, Sims C, Richards S, Ray J Cureus. 2024; 16(10):e72234.

PMID: 39583391 PMC: 11585378. DOI: 10.7759/cureus.72234.

The potential use of therapeutics and prophylactic mRNA vaccines in human papillomavirus (HPV).

Movahed F, Darzi S, Mahdavi P, Mahdi M, Allela O, Sameer H Virol J. 2024; 21(1):124.

PMID: 38822328 PMC: 11143593. DOI: 10.1186/s12985-024-02397-9.

mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications.

Wang Y, Kumari M, Chen G, Hong M, Yuan J, Tsai J J Biomed Sci. 2023; 30(1):84.

PMID: 37805495 PMC: 10559634. DOI: 10.1186/s12929-023-00977-5.

Dengue virus 3 genotype I (GI) lineage 1 (L1) isolates elicit differential cytopathic effect with syncytium formation in human glioblastoma cells (U251).

de Souza Andrade A, Oliveira Campos S, Dias J, Campos M, Kroon E Virol J. 2023; 20(1):204.

PMID: 37661255 PMC: 10476378. DOI: 10.1186/s12985-023-02168-y.

Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: vs. approach.

Norshidah H, Leow C, Ezleen K, Wahab H, Vignesh R, Rasul A Front Cell Infect Microbiol. 2023; 13:1061937.

PMID: 36864886 PMC: 9971573. DOI: 10.3389/fcimb.2023.1061937.

References

Leitmeyer K, Vaughn D, Watts D, Salas R, Villalobos I, de Chacon . Dengue virus structural differences that correlate with pathogenesis. J Virol. 1999; 73(6):4738-47. PMC: 112516. DOI: 10.1128/JVI.73.6.4738-4747.1999. View

Proutski V, Gritsun T, Gould E, Holmes E . Biological consequences of deletions within the 3'-untranslated region of flaviviruses may be due to rearrangements of RNA secondary structure. Virus Res. 1999; 64(2):107-23. DOI: 10.1016/s0168-1702(99)00079-9. View

Ni H, Ryman K, Wang H, Saeed M, Hull R, Wood D . Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants. J Virol. 2000; 74(6):2903-6. PMC: 111783. DOI: 10.1128/jvi.74.6.2903-2906.2000. View

Kanesa-thasan N, Sun W, Van Albert S, Putnak J, King A, Raengsakulsrach B . Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine. 2001; 19(23-24):3179-88. DOI: 10.1016/s0264-410x(01)00020-2. View

Guirakhoo F, Arroyo J, Pugachev K, Miller C, Zhang Z, Weltzin R . Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol. 2001; 75(16):7290-304. PMC: 114964. DOI: 10.1128/JVI.75.16.7290-7304.2001. View

Konishi E, Fujii A . Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine. 2002; 20(7-8):1058-67. DOI: 10.1016/s0264-410x(01)00446-7. View

Kroeger M, McMinn P . Murray Valley encephalitis virus recombinant subviral particles protect mice from lethal challenge with virulent wild-type virus. Arch Virol. 2002; 147(6):1155-72. DOI: 10.1007/s00705-002-0809-3. View

Blaney Jr J, Johnson D, Manipon G, Firestone C, Hanson C, Murphy B . Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology. 2002; 300(1):125-39. DOI: 10.1006/viro.2002.1528. View

Hanley K, Manlucu L, Gilmore L, Blaney Jr J, Hanson C, Murphy B . A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. Virology. 2003; 312(1):222-32. DOI: 10.1016/s0042-6822(03)00197-1. View

10.

Markoff L . 5'- and 3'-noncoding regions in flavivirus RNA. Adv Virus Res. 2003; 59:177-228. PMC: 7119107. DOI: 10.1016/s0065-3527(03)59006-6. View

11.

Modis Y, Ogata S, Clements D, Harrison S . Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004; 427(6972):313-9. DOI: 10.1038/nature02165. View

12.

Edelman R, Wasserman S, Bodison S, Putnak R, Eckels K, Tang D . Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg. 2004; 69(6 Suppl):48-60. DOI: 10.4269/ajtmh.2003.69.48. View

13.

Zhang Y, Zhang W, Ogata S, Clements D, Strauss J, Baker T . Conformational changes of the flavivirus E glycoprotein. Structure. 2004; 12(9):1607-18. PMC: 4152830. DOI: 10.1016/j.str.2004.06.019. View

14.

Pryor M, Azzola L, Wright P, Davidson A . Histidine 39 in the dengue virus type 2 M protein has an important role in virus assembly. J Gen Virol. 2004; 85(Pt 12):3627-3636. DOI: 10.1099/vir.0.80283-0. View

15.

Yon C, Teramoto T, Mueller N, Phelan J, Ganesh V, Murthy K . Modulation of the nucleoside triphosphatase/RNA helicase and 5'-RNA triphosphatase activities of Dengue virus type 2 nonstructural protein 3 (NS3) by interaction with NS5, the RNA-dependent RNA polymerase. J Biol Chem. 2005; 280(29):27412-9. DOI: 10.1074/jbc.M501393200. View

16.

Li J, Pheng Lim S, Beer D, Patel V, Wen D, Tumanut C . Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem. 2005; 280(31):28766-74. DOI: 10.1074/jbc.M500588200. View

17.

Alvarez D, De Lella Ezcurra A, Fucito S, Gamarnik A . Role of RNA structures present at the 3'UTR of dengue virus on translation, RNA synthesis, and viral replication. Virology. 2005; 339(2):200-12. DOI: 10.1016/j.virol.2005.06.009. View

18.

Butrapet S, Kinney R, Huang C . Determining genetic stabilities of chimeric dengue vaccine candidates based on dengue 2 PDK-53 virus by sequencing and quantitative TaqMAMA. J Virol Methods. 2005; 131(1):1-9. DOI: 10.1016/j.jviromet.2005.06.019. View

19.

Miller S, Sparacio S, Bartenschlager R . Subcellular localization and membrane topology of the Dengue virus type 2 Non-structural protein 4B. J Biol Chem. 2006; 281(13):8854-63. DOI: 10.1074/jbc.M512697200. View

20.

Sanchez V, Gimenez S, Tomlinson B, Chan P, Neil Thomas G, Forrat R . Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine. 2006; 24(23):4914-26. DOI: 10.1016/j.vaccine.2006.03.066. View